DLL3 expression and clinico-pathological data in 247 patients with NEN

#3514

Introduction: Delta-like protein 3 (DLL3) is currently under clinical investigation as a potential therapeutic target in small cell neuroendocrine lung cancer. Characterization of the levels and patterns of DLL3 expression in other neuroendocrine neoplasms (NEN) is limited.

Aim(s): The aim of this study was to investigate the expression of DLL3 in NEN and to correlate data with the clinical and pathological profiles.

Materials and methods: Immunohistochemical analysis of DLL3 (SC16.65) was performed on 247 freshly cut histological sections from paraffin blocks of primary tumors or metastases of NEN. DLL3 was scored positive if 1% of tumor cells displayed membranous, cytoplasmic, granular, or dot-like immunostaining. The intensity of staining was scored as 0, 1+, 2+ and 3+, and the percentage of each staining intensity evaluated. The total percentage of tumor cells stained was recorded.

Conference:

Presenting Author: Clausen M

Authors: Clausen M, Federspiel B, Carstensen F, Suppli M, Kjaer A,

Keywords: DLL3, high-grade NEN,